WO2003002755A3 - Glaucoma treatments with reduced hyperpigmentation - Google Patents

Glaucoma treatments with reduced hyperpigmentation Download PDF

Info

Publication number
WO2003002755A3
WO2003002755A3 PCT/US2002/019295 US0219295W WO03002755A3 WO 2003002755 A3 WO2003002755 A3 WO 2003002755A3 US 0219295 W US0219295 W US 0219295W WO 03002755 A3 WO03002755 A3 WO 03002755A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperpigmentation
reduced
glaucoma treatments
ability
methods
Prior art date
Application number
PCT/US2002/019295
Other languages
French (fr)
Other versions
WO2003002755A2 (en
Inventor
David F Woodward
Licheng Shi
Achim H P Krauss
Clayton S Spada
Neil Sheila Mac
Linda C Smith-Thomas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to JP2003508719A priority Critical patent/JP2005522183A/en
Priority to EP02744415A priority patent/EP1399738A2/en
Priority to CA002451129A priority patent/CA2451129A1/en
Publication of WO2003002755A2 publication Critical patent/WO2003002755A2/en
Publication of WO2003002755A3 publication Critical patent/WO2003002755A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.
PCT/US2002/019295 2001-06-26 2002-06-18 Glaucoma treatments with reduced hyperpigmentation WO2003002755A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003508719A JP2005522183A (en) 2001-06-26 2002-06-18 Glaucoma treatment with decreased hyperpigmentation
EP02744415A EP1399738A2 (en) 2001-06-26 2002-06-18 Glaucoma treatments with reduced hyperpigmentation
CA002451129A CA2451129A1 (en) 2001-06-26 2002-06-18 Glaucoma treatments with reduced hyperpigmentation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/893,159 US6713268B2 (en) 2001-06-26 2001-06-26 Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US09/893,159 2001-06-26

Publications (2)

Publication Number Publication Date
WO2003002755A2 WO2003002755A2 (en) 2003-01-09
WO2003002755A3 true WO2003002755A3 (en) 2003-11-13

Family

ID=25401116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019295 WO2003002755A2 (en) 2001-06-26 2002-06-18 Glaucoma treatments with reduced hyperpigmentation

Country Status (5)

Country Link
US (1) US6713268B2 (en)
EP (1) EP1399738A2 (en)
JP (1) JP2005522183A (en)
CA (1) CA2451129A1 (en)
WO (1) WO2003002755A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7302830B2 (en) * 2001-06-06 2007-12-04 Symyx Technologies, Inc. Flow detectors having mechanical oscillators, and use thereof in flow characterization systems
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
JP2008505978A (en) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド Ophthalmic composition and eye disease treatment method
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
BR122017013201B1 (en) 2009-11-09 2018-05-15 Allergan, Inc. COMPOSITION FOR STIMULATION OF HAIR GROWTH
CN109602691A (en) 2013-02-15 2019-04-12 阿勒根公司 Sustained drug delivery implantation material

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364417A1 (en) * 1988-09-06 1990-04-18 Pharmacia AB Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5689281A (en) * 1994-06-28 1997-11-18 Sharp Kabushiki Kaisha Liquid crystal display apparatus
WO1999002165A1 (en) * 1997-07-11 1999-01-21 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
WO2000025771A1 (en) * 1998-11-04 2000-05-11 Synphora Ab Method for preventing increased iridial pigmentation during prostaglandin treatment
WO2001068072A2 (en) * 2000-03-16 2001-09-20 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
WO2002007731A2 (en) * 2000-07-20 2002-01-31 Sucampo Ag Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6458836B1 (en) * 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364417A1 (en) * 1988-09-06 1990-04-18 Pharmacia AB Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5689281A (en) * 1994-06-28 1997-11-18 Sharp Kabushiki Kaisha Liquid crystal display apparatus
WO1999002165A1 (en) * 1997-07-11 1999-01-21 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
WO2000025771A1 (en) * 1998-11-04 2000-05-11 Synphora Ab Method for preventing increased iridial pigmentation during prostaglandin treatment
WO2001068072A2 (en) * 2000-03-16 2001-09-20 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
WO2002007731A2 (en) * 2000-07-20 2002-01-31 Sucampo Ag Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALM A: "Prostaglandin derivates as ocular hypotensive agents", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 17, no. 3, 1997, pages 291 - 312, XP002078919, ISSN: 1350-9462 *
BRANDT J D ET AL: "Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial.", OPHTHALMOLOGY. UNITED STATES JUN 2001, vol. 108, no. 6, June 2001 (2001-06-01), pages 1023 - 1031;discussion 1032, XP001153494, ISSN: 0161-6420 *
GRIFFIN B W ET AL: "FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 281, no. 2, 1997, pages 845 - 854, XP002249086, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
WO2003002755A2 (en) 2003-01-09
US6713268B2 (en) 2004-03-30
US20030018078A1 (en) 2003-01-23
JP2005522183A (en) 2005-07-28
EP1399738A2 (en) 2004-03-24
CA2451129A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
WO2003002755A3 (en) Glaucoma treatments with reduced hyperpigmentation
HK1043934A1 (en) Treatment for dentin sensitivity with aqueous dispersions of hydrophobe-co-hydrophile copolymers
EP1178786A4 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
AU2001288686A1 (en) Improved cardiac function through administration of es cells
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
WO2006102498A3 (en) Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
MXPA02008402A (en) Derivatives of quinoline as alpha-2 antagonists.
WO2001006261A3 (en) Screening for therapeutic agents being scap antagonists
PT1175224E (en) HIV COMBINATION THERAPY WITH PEGUILED ALPHA INTERPHANT AND A CCR5 ANTAGONIST
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2002059346A3 (en) Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
GC0000250A (en) 5-Ä4-Ä2-(N-methyl-n-(2-pyridyl) amino) ethoxyÜ benzylÜthiazolidine-2,4-dione maleci acid salt
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
AU2001293064A1 (en) Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
AU2003221527A1 (en) Method for examining the ocular fundus
WO2000050426A3 (en) Furo[3, 2-b]pyridines as 5-ht1f agonists
AU2001264097A1 (en) 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity
WO2006055573A3 (en) Methods of using pde v inhibitors for the treatment of congestive heart failure
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
AU2002341044A1 (en) Methods for detecting parkinson's disease
BR0012447A (en) N-acyl side chain pseudomycin analogs
WO2003051297A3 (en) Aqueous ifosfamide composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002344785

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2451129

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002744415

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003508719

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002744415

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642